Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
Background: Irritable bowel syndrome is classified as a functional gastrointestinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel movement disorder. It affects up to 15% of the world’s population. Among its subtypes, the most common is diarrhoea predomina...
Main Authors: | Kamesh Gupta, Harparam Singh Ghuman, Shivani Vijay Handa |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-08-01
|
Series: | Clinical Medicine Insights: Gastroenterology |
Online Access: | https://doi.org/10.1177/1179552217728905 |
Similar Items
-
Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-01-01) -
Rifaximin Therapy of Irritable Bowel Syndrome
by: Hoonmo L. Koo, et al.
Published: (2012-06-01) -
Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
by: Iorio N, et al.
Published: (2015-06-01) -
Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01) -
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
by: William D. Chey, et al.
Published: (2020-01-01)